What did @karinasbiohacking actually say?
The claim is that stacking mitochondrial peptides like "SLU" (likely MOTS-c or a similar compound) and "MOTSE" (almost certainly MOTS-c) can cause "proton electron slip," generating reactive oxygen species and triggering an immune response that leaves you fatigued or tachycardic. The fix, she says, is SS-31, which can "correct that leak and slip." She also says heavy breathing is a sign you are "leaking and slipping protons and electrons."
This is a mix of real mitochondrial biology, loosely applied terminology, and some genuinely unsupported extrapolations, all delivered as if it were established clinical protocol. It is not.
Does the science back this up?
Partly, but the framing is sloppy in ways that matter. Mitochondrial proton leak is a real phenomenon, and SS-31 (elamipretide) does have legitimate research behind it, mostly in animal models and early human trials for heart failure and mitochondrial disease.
Proton leak refers to protons crossing the inner mitochondrial membrane without driving ATP synthesis, which can increase reactive oxygen species (ROS) production. This is documented biology. Bharat Bhanu Prasad et al. and earlier work by Brand (2000, Experimental Gerontology) confirmed that proton leak accounts for a significant portion of basal metabolic oxygen consumption. SS-31 works by targeting cardiolipin on the inner mitochondrial membrane, stabilizing electron transport chain complexes and reducing ROS. Szeto and Schiller described this mechanism in detail (Szeto, 2014, Journal of Cardiovascular Pharmacology). That part is real science.
The leap, however, from "I am taking too many peptides" to "my mitochondria are spinning too much and slipping electrons" is not supported by any published human trial. There is no clinical evidence that stacking MOTS-c or similar peptides produces a measurable proton leak in otherwise healthy people.
What did they get wrong (or right)?
Right: SS-31 does target the inner mitochondrial membrane and has demonstrated ROS-reducing effects in preclinical and some early clinical settings. Tachycardia and fatigue are legitimate reasons to stop any unproven peptide stack. Cycling compounds rather than running them indefinitely is a reasonable harm-reduction instinct, even if the reasoning here is muddled.
Wrong: The phrase "proton electron slip" is not standard biochemistry. Proton leak is a thing. Electron slip (superoxide formation at complex I and III) is a thing. Conflating them into a single mechanism caused by peptide overuse is not a documented phenomenon. Tachycardia and fatigue from peptide stacking have many more plausible explanations, including injection site reactions, hormonal perturbation, or simple overtraining, none of which SS-31 addresses.
Also wrong: Describing heavy breathing as literal electron leakage is physiologically incoherent. Heavy breathing during exertion reflects increased oxygen demand and CO2 clearance. That is not proton slip. Saying otherwise to a 17,000-person audience without any qualifier is the kind of oversimplification that gets people to self-diagnose based on a TikTok.
What should you actually know?
SS-31 (elamipretide) is an investigational peptide. As of 2024, it has not been approved by the FDA for any indication. Stealth BioTherapeutics ran phase 3 trials for Barth syndrome and primary mitochondrial myopathy; results were mixed and the company faced significant financial difficulties. Govari et al. (2020, JACC: Basic to Translational Science) showed some promising data in heart failure with preserved ejection fraction, but that is a specific disease population, not biohackers who feel winded.
The peptides called "SLU" and "MOTSE" in this video likely refer to compounds in the MOTS-c or humanin family, small mitochondria-derived peptides with genuine research interest. But that research is almost entirely in rodents or cell lines. Using them in humans, cycling them based on symptom interpretation, and then self-administering SS-31 as a corrective agent is a series of steps with no clinical evidence base and real unknown risks.
If you are tachycardic or persistently fatigued while using unregulated peptides, the appropriate response is to stop all of them and talk to a physician, not add another compound to the stack.
Bottom line
The underlying mitochondrial biology here is not invented. Proton leak, ROS generation, and SS-31's cardiolipin-targeting mechanism are all documented in peer-reviewed literature. But the creator is applying these concepts to a self-dosing human context that the research does not support, using non-standard terminology with apparent confidence, and recommending a specific peptide intervention for symptoms that could indicate something requiring actual medical evaluation. That is the part worth pushing back on.